BMI Seminar // Use of human genome variation to invigorate drug discovery and development
Event details
| Date | 29.05.2013 |
| Hour | 12:15 › 13:15 |
| Speaker |
Vincent Mooser Service de biomédecine Unil - Université de Lausanne, Switzerland |
| Location |
SV1717A
|
| Category | Conferences - Seminars |
Abstract
Recent discoveries of an abundance of rare functional variants in the human genome open up new opportunities to invigorate drug discovery and development. More specifically, these “gifts by nature” can be used for drug target identification and validation, shortcutting the need to translate data from animal or cellular models into humans. Moreover, the presence of naturally occurring functional genetic variants makes it possible to contemplate a new generation of more decisive, smaller and faster proof-of-concept studies. Here, investigational drugs are tested early in their development in individuals who have the highest chance to respond to, and benefit from the intervention, i.e. those who carry a genetic variant which functionally mirrors the effect of the intervention. The presentation will illustrate the power of these gene-based (i.e. Mendelian) approaches and describe the unique platform, including a large biobank, which is being constructed locally to collect tangible fruits of the “genomic revolution".
Recent discoveries of an abundance of rare functional variants in the human genome open up new opportunities to invigorate drug discovery and development. More specifically, these “gifts by nature” can be used for drug target identification and validation, shortcutting the need to translate data from animal or cellular models into humans. Moreover, the presence of naturally occurring functional genetic variants makes it possible to contemplate a new generation of more decisive, smaller and faster proof-of-concept studies. Here, investigational drugs are tested early in their development in individuals who have the highest chance to respond to, and benefit from the intervention, i.e. those who carry a genetic variant which functionally mirrors the effect of the intervention. The presentation will illustrate the power of these gene-based (i.e. Mendelian) approaches and describe the unique platform, including a large biobank, which is being constructed locally to collect tangible fruits of the “genomic revolution".
Practical information
- Informed public
- Free
Organizer
- SV-BMI
Host : Prof. P. Aebischer